

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

VALVE SOCKET INC. 1800-2111

TAF-14

07/835964

APPLICANT

Coates et al

FILING DATE
February 20, 1992

GROUP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 212 409 B1	3/4/87	Europe	317	36		
	EP 0 302 760	6/6/88	Europe	31	70		
	EP 0 337 713 A2	10/18/89	Europe	473	32		
	EP 0 349 242 A2	1/3/90	Europe	473	00		
	EP 0 363 582 A1	4/18/90	Europe	405	06		
	EP 0 382 526 A2	2/8/89	Europe	473	00		
	EP 0 421 777 A1	4/10/91	Europe	19	067		
	GB 2 063 257 A	6/3/81	Great Britain	239	54		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Baba et al., "Both 2',3'-Dideoxythymidine and its 2',3'-Unsaturated Derivative (2',3'-Dideoxythymidinene) are Potent and Selective Inhibitors of Human Immunodeficiency Virus Replication in vitro", Biochemical and Biophysical Research Communications, 142(1) pp. 128-134 (1987) ("Baba").

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM 1610-0448	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	Serial No.
		IAF-14	07/835964
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT	
		Coates et al	
		FILING DATE	GROUP
		February 20, 1992	120

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	GB 2 230 266 A	10/17/90	Great Britain	49	04		
	WO 89/04662	6/1/89	PCT	31	66		
	WO 90/12023	10/18/90	PCT	19	10		
	WO 91/00282	1/10/91	PCT	473	00		
	WO 91/01326	2/7/91	PCT	19	073		
	WO 91/11186	8/8/91	PCT	31	505		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Balzarini et al., "Potent and Selective Anti-HTLV-III/LAV Activity of 2',3'-Dideoxycytidinene, the 2',3'-Unsaturated Derivative of 2',3'-Dideoxycytidine", Biochemical and Biophysical Research Communications, 140(2), pp. 735-742 (1986) ("Balzarini").

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY. DOCKET NO.	SERIAL NO.
IAF-14	07/835964
APPLICANT	
Coates et al	

FILING DATE
February 20, 1992GROUP
1202

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER
INITIAL

OF
Belleau et al., "Design And Activity Of A Novel Class Of Nucleoside Analogs Effective Against HIV-1", Fifth International Conference on AIDS, Montreal, Canada, Abstract T.C.O. 1 (1989) ("Belleau").

Carlisle et al., "Cellular Pharmacology Of The Anti-HIV Agent BCH-189 (2'Deoxy-3'-Thiacytidine) In Human Peripheral Blood Mononuclear Cells (PBMC)", American Association for Cancer Research Proceedings, 31, abstract 2435, (1990) ("Carlisle").

Gosselin et al., "Systematic Synthesis And Biological Evaluation Of α - and β -D-Lyxofuranosyl Nucleotides Of The Five naturally Occurring Nucleic Acid Bases", J. Med. Chem., 30, pp. 1270-1278 (1987) ("Gosselin").

Herdewijn et al., "3'-Substituted 2',3'-Dideoxynucleoside Analogues as Potential as Potential anti-HIV (HTLV-III/LAV) Agents", J. Med. Chem., 30, pp. 1270-1278 (1987) ("Herdewijn").

Lin et al., "Synthesis and Antiviral Activity of Various 3'-Azido, 3'-Amino, 2',3'-Unsaturated, and 2',3'-Dideoxy Analogues of Pyrimidine Deoxyribonucleosides against Retroviruses", J. Med. Chem., 30, pp. 440-444 (1987) ("Lin").

Mitsuya et al., "3'-Azido-3'-Deoxythymidine (BW A509U): An Antiviral Agent that Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus in vitro", Proc. Natl. Acad. Sci. USA, 82, pp. 7096-7100 (1986) ("Mitsuya-1").

Mitsuya et al. "Inhibition of the in vitro Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus (HTLV-III/LAV) by 2', 3'-Dideoxynucleosides", Proc. Natl. Acad. Sci. USA, 83, pp. 1911-1915 (1986) ("Mitsuya-2").

OF
Wainberg et al., "Anti-HIV Activity, Toxicity And Pharmacokinetics Of Totally Novel Nucleoside Analogs," Fifth International Conference on AIDS, Montreal, Canada, Abstract M.C.P. 63, p. 552, (1989) ("Wainberg-1").

EXAMINER

DATE CONSIDERED
12-24-92

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM GTO-1349

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY. DOCKET NO.	SERIAL NO.
IAF-14	07/835964
APPLICANT	
Coates et al	
FILING DATE	GROUP
February 20, 1992	1202

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER
INITIAL


Wainberg et al., "Characterization Of AZT-Resistant Isolates Of HIV-1: Susceptibility To Deoxythiacytidine And Other Nucleosides", Sixth International Conference on AIDS, San Francisco, California, Volume 3, Abstract S.B.87, p. 117 (1990) ("Wainberg-2").

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.